608 related articles for article (PubMed ID: 31912907)
1. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
[TBL] [Abstract][Full Text] [Related]
2. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
3. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
[TBL] [Abstract][Full Text] [Related]
4. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
6. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
[TBL] [Abstract][Full Text] [Related]
7. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
8. Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.
Hwang EC; Sathianathen NJ; Jung JH; Kim MH; Dahm P; Risk MC
Cochrane Database Syst Rev; 2019 May; 5(5):CD013160. PubMed ID: 31102534
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for advanced or metastatic urothelial carcinoma.
Maisch P; Hwang EC; Kim K; Narayan VM; Bakker C; Kunath F; Dahm P
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013774. PubMed ID: 37811690
[TBL] [Abstract][Full Text] [Related]
11. Robotic versus open radical cystectomy for bladder cancer in adults.
Rai BP; Bondad J; Vasdev N; Adshead J; Lane T; Ahmed K; Khan MS; Dasgupta P; Guru K; Chlosta PL; Aboumarzouk OM
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD011903. PubMed ID: 31016718
[TBL] [Abstract][Full Text] [Related]
12. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
13. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013776. PubMed ID: 34850382
[TBL] [Abstract][Full Text] [Related]
14. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
[TBL] [Abstract][Full Text] [Related]
16. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
17. Robot-assisted vs open radical cystectomy for bladder cancer in adults.
Rai BP; Bondad J; Vasdev N; Adshead J; Lane T; Ahmed K; Khan MS; Dasgupta P; Guru K; Chlosta PL; Aboumarzouk OM
BJU Int; 2020 Jun; 125(6):765-779. PubMed ID: 31309688
[TBL] [Abstract][Full Text] [Related]
18. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
[TBL] [Abstract][Full Text] [Related]
20. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.
Kunath F; Jensen K; Pinart M; Kahlmeyer A; Schmidt S; Price CL; Lieb V; Dahm P
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD003506. PubMed ID: 31194882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
